✦ LIBER ✦

Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

✍ Scribed by Lee, J. S.; Hirsh, V.; Park, K.; Qin, S.; Blajman, C. R.; Perng, R.-P.; Chen, Y.-M.; Emerson, L.; Langmuir, P.; Manegold, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9005 Vandetanib versus erlotinib in pati

✍ Goss, G.D.; Thongprasert, S.; Greco, F.A.; Thomas, M.; Tsai, C.M.; Sunpaweravong 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

9004 Vandetanib plus pemetrexed vs pemet

✍ Vansteenkiste, J.; Arrieta, O.; Gottfried, M.; Blackhall, F.H.; Raats, J.; Yang, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

53LBA A phase I/IIa study of icotinib hy

✍ Q. Zhao; J. Zhou; J. Shentu; L. Wu; N. Xu; F. Tan; Y. Wang; D. Yang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A phase I and pharmacokinetic study of d

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB